CA2242579A1 - Antagonistes benzimidazolyles du recepteur du neuropeptide y - Google Patents

Antagonistes benzimidazolyles du recepteur du neuropeptide y Download PDF

Info

Publication number
CA2242579A1
CA2242579A1 CA002242579A CA2242579A CA2242579A1 CA 2242579 A1 CA2242579 A1 CA 2242579A1 CA 002242579 A CA002242579 A CA 002242579A CA 2242579 A CA2242579 A CA 2242579A CA 2242579 A1 CA2242579 A1 CA 2242579A1
Authority
CA
Canada
Prior art keywords
alkylenyl
alkoxy
heterocyclic
phenyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002242579A
Other languages
English (en)
Inventor
Macklin Brian Arnold
Thomas Charles Britton
Robert Frederick Junior Bruns
Buddy Eugene Cantrell
Anne Marie Nunes
Philip Arthur Hipskind
James Jeffry Howbert
Karen Lynn Lobb
James Arthur Nixon
Paul Leslie Ornstein
Edward C. R. Smith
Hamideh Zarrinmayeh
Dennis Michael Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9600344.7A external-priority patent/GB9600344D0/en
Application filed by Individual filed Critical Individual
Publication of CA2242579A1 publication Critical patent/CA2242579A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une série de benzimidazoles substitués qui sont utiles dans le traitement ou la prévention d'un état associé à un excès de neuropeptides Y. L'invention concerne également des procédés mettant en application ces benzimidazoles substitués, ainsi que des formulations pharmaceutiques comprenant un ou plusieurs de ces composés en tant que principe actif.
CA002242579A 1996-01-09 1997-01-09 Antagonistes benzimidazolyles du recepteur du neuropeptide y Abandoned CA2242579A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9600344.7A GB9600344D0 (en) 1996-01-09 1996-01-09 Benzimidzolyl neuropeptide y receptor antagonists
GB9600344.7 1996-01-09
US2163696P 1996-07-12 1996-07-12
US60/021,636 1996-07-12

Publications (1)

Publication Number Publication Date
CA2242579A1 true CA2242579A1 (fr) 1997-07-17

Family

ID=26308442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002242579A Abandoned CA2242579A1 (fr) 1996-01-09 1997-01-09 Antagonistes benzimidazolyles du recepteur du neuropeptide y

Country Status (5)

Country Link
EP (1) EP0871442A1 (fr)
JP (1) JP2000501107A (fr)
AU (1) AU2242197A (fr)
CA (1) CA2242579A1 (fr)
WO (1) WO1997025041A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
CN1264381A (zh) 1997-08-05 2000-08-23 辉瑞产品公司 4-氨基吡咯并(3,2-d)嘧啶作为神经肽Y受体拮抗药
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
DE19801648A1 (de) * 1998-01-17 1999-07-22 Bayer Ag alpha-Substituierte Lactone
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2002046168A1 (fr) * 2000-12-07 2002-06-13 Astrazeneca Ab Composes therapeutiques de benzimidazole
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2485725A1 (fr) 2002-06-05 2003-12-18 F. Hoffmann-La Roche Ag Derives de 1-sulfonyl-4-aminoalcoxy-indole et leur utilisation comme modulateurs des recepteurs 5-ht6 en traitement de troubles du snc
WO2004098591A2 (fr) 2003-05-05 2004-11-18 Probiodrug Ag Inhibiteurs de glutaminyl-cyclase
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (fr) 2004-02-05 2014-04-29 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase comportant de la n thiouree alkyle et de l'imidazolyl substitue par thioamide
CN100567270C (zh) 2004-02-19 2009-12-09 万有制药株式会社 磺酰胺衍生物
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
MX2011001887A (es) 2008-08-22 2011-04-04 Baxter Int Derivados de bencil carbonato polimericos.
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
US9388140B2 (en) 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
CN103965113A (zh) * 2014-05-06 2014-08-06 四川大学 1-羟乙基-2-取代苯氧甲基苯并咪唑类化合物及其制备方法
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP6400869B1 (ja) * 2018-02-23 2018-10-03 日本曹達株式会社 4,5−ジシアノ−2−(フルオロアルキル)イミダゾールの製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772703A (en) * 1986-01-27 1988-09-20 American Home Products Corporation 2-(phenoxymethyl)-quinazolines as antiallergic and antiinflammatory agents

Also Published As

Publication number Publication date
JP2000501107A (ja) 2000-02-02
EP0871442A1 (fr) 1998-10-21
WO1997025041A1 (fr) 1997-07-17
AU2242197A (en) 1997-08-01

Similar Documents

Publication Publication Date Title
CA2242579A1 (fr) Antagonistes benzimidazolyles du recepteur du neuropeptide y
US5574044A (en) Muscarine antagonists
US6340681B1 (en) 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6025372A (en) Somatostatin agonists
US6642228B1 (en) α1b-adrenergic receptor antagonists
AU717422B2 (en) Indolyl neuropeptide Y receptor antagonists
DE60119939T2 (de) Chinolinderivate als antibakterielle mittel
JP2000512296A (ja) セロトニン再取込み阻害
JP3315970B2 (ja) ニューロキニンアンタゴニストとしてのピペラジノ誘導体
US7202245B2 (en) Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
US20030191164A1 (en) Propane-1,3-dione derivatives
SK404491A3 (en) Tricyclic lactam compounds, pharmaceutical compositions comprising same and their use
CZ289479B6 (cs) Pouľití piperidinových derivátů pro výrobu farmaceutických prostředků, piperidinové deriváty a farmaceutický prostředek
AU2006275568A1 (en) Dipiperazinyl ketones and related analogues
US6960589B2 (en) Benzimidazoles that are useful in treating sexual dysfunction
JP4870163B2 (ja) Mch受容体アンタゴニストとしてのインダン誘導体
EP1373220B1 (fr) Benzimidazoles utiles dans le traitement de troubles sexuels
US20040127504A1 (en) Benzimidazoles that are useful in treating sexual dysfunction
US6255494B1 (en) Benzimidzolyl neuropeptide Y receptor antagonists
CN100509805C (zh) 3,4-二氢-1h-异喹啉-2-基-衍生物
US7351828B2 (en) Benzimidazoles that are useful in treating sexual dysfunction
US6506756B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US5776931A (en) Naphthimidazolyl neuropeptide Y receptor antagonists
DK170506B1 (da) Pyrido- og azepino-indolforbindelser, fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende dem samt anvendelse af forbindelserne
JP2002047287A (ja) 芳香族誘導体

Legal Events

Date Code Title Description
FZDE Dead